Belle Gibson is the latest fraudster to have a TV show made on how she swindled people out of money by pretending healthy eating and green juices cured her brain cancer. However, it soon became ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

Adrenal tumors are a heterogeneous group of tumors characterized by diverse biology and clinical courses. They may be associated with high malignant potential and/or hormonal activity, leading to ...

Ear cancer is when abnormal cells in the ear start to grow and divide in an uncontrolled way. Most of these cancers start in the skin of the outer ear. Cancers that develop inside the ear, known as ...

The US Food and Drug Administration (FDA) will soon decide on whether to expand the label of MSD’s Welireg (belzutifan) to include its use for the treatment of the rare cancer pheochromocytoma and ...

to include its use for the treatment of the rare cancer pheochromocytoma and paraganglioma (PPGL). The regulatory agency will review MSD’s new drug application (NDA) for Welireg under a Priority ...

Merck & Co (NYSE:MRK) said on Monday that the U.S. Food and Drug Administration (FDA) has granted priority review to its application for expanded use of the oral cancer drug Welireg.

Comparative outcomes of neuroendocrine tumors in the historically underserved population of Bronx, NY: Montefiore Einstein Comprehensive Cancer Center. Pamrevlumab ...

Background: UCK2 (Uridine-Cytidine Kinase 2) is a promising prognostic marker for malignant tumors, but its association with immune infiltration and cancer stemness in pan-cancer remains to be fully ...

A ketogenic diet may have health benefits for the treatment or prevention of cancer. But research is mixed, and it can have downsides for people receiving ongoing cancer treatment. Cancer is most ...

Lung cancer survival without treatment is shorter than survival with treatment. People with untreated non-small cell lung cancer—the most common type—typically live between five and 12 months after ...